title: Response letter to D. Singh-franco et al.
authors.forename: D R
authors.initials: DR
authors.lastname: Owens
authors.forename: S
authors.initials: S
authors.lastname: Del Prato
authors.forename: M R
authors.initials: MR
authors.lastname: Taskinen
authors.forename: R
authors.initials: R
authors.lastname: Gomis
authors.forename: T
authors.initials: T
authors.lastname: Forst
authors.forename: H-J
authors.initials: HJ
authors.lastname: Woerle
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage*; D011687:Purines / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D045162:Thiazolidinediones; D008687:Metformin